EuBiotics Typhoid Vaccine EuTYPH-C Secures WHO Prequalification, Unlocking Global Procurement Access

The Quick Take

• Korean vaccine company EuBiotics has obtained WHO Prequalification for its typhoid conjugate vaccine EuTYPH-C, unlocking access to UNICEF and international procurement markets
• The WHO PQ milestone represents EuBiotics' entry into the global public vaccine supply market alongside established international manufacturers
• Korea's MFDS partnering with WHO for Asia-Pacific biosimilar regulatory workshops signals a broader regulatory capacity expansion

Korean vaccine developer EuBiotics has obtained WHO Prequalification for its typhoid conjugate vaccine EuTYPH-C Inj., a regulatory milestone that opens access to UNICEF and other international procurement bodies that supply vaccines to underserved markets globally. The WHO PQ is one of the most stringent quality evaluations in global vaccine manufacturing and its acquisition signals that EuBiotics' production standards meet international benchmarks. The company's expansion into typhoid — a disease burden concentrated in lower-income countries — represents a strategic extension of its public vaccine portfolio beyond its established domestic Korean market.

The WHO PQ for EuTYPH-C positions EuBiotics in a limited pool of qualified typhoid conjugate vaccine suppliers, creating a structural advantage in UNICEF and Gavi procurement tenders where WHO qualification is often a prerequisite. For the Korean biotechnology sector, this milestone validates the quality of domestic vaccine manufacturing infrastructure and strengthens South Korea's credibility as a global health supply partner — a position the country has actively cultivated since its COVID-19 vaccine development push. Peer Korean vaccine manufacturers may accelerate their own WHO PQ applications in adjacent disease categories.

The key forward signals are whether EuBiotics converts the WHO PQ into actual procurement contracts with UNICEF, Gavi, or bilateral aid agencies — which would translate the regulatory milestone into recurring revenue. UNICEF's annual typhoid vaccine procurement volume data and Gavi's advance market commitment timelines are the macro variables that determine the commercial scale EuBiotics can realistically access. Korea's MFDS co-hosting WHO biosimilar regulatory workshops suggests a parallel regulatory capacity expansion across the Korean healthcare sector.

Synthesized from 3 sources.